Orexo
23.45 SEK
+0.86 %
Less than 1K followers
ORX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+0.86 %
-16.55 %
-16.55 %
+19.04 %
+34.00 %
+6.83 %
+16.67 %
-51.04 %
-73.93 %
Orexo is a Swedish pharmaceutical company that develops improved medicines based on proprietary formulation technologies and with a focus on meeting major medical needs. In the US market, Orexo commercializes treatments for patients suffering from opioid addiction. Products targeting other therapeutic areas are developed and commercialized worldwide through partners.
Read moreMarket cap
871.32M SEK
Turnover
1.43M SEK
Revenue
590M
EBIT %
-23.78 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
5/2
2026
Annual report '25
28/4
2026
Interim report Q1'26
7/5
2026
General meeting '26
All
Webcasts
Press releases
3rd party
ShowingAll content types
DNB Carnegie Access: Orexo: Deal delay behind share price drop – Q3 review
DNB Carnegie Access: Orexo: No major surprises – Q3 initial comment
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools